Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease

Table 2 Clinical characteristics of patients at 24-week after medication treatment (n = 30 for each group)

Variables	Section 1			Section 2
Variables	Liraglutide monotherapy	Metformin monotherapy	P	Liraglutide (1.8 mg/d) monotherapy	Liraglutide plus Metformin dual therapy	P
BMI (kg/m²)	28.37 ± 1.72	28.70 ± 1.87	0.480	28.65 ± 1.77	28.42 ± 1.74	0.614
FPG c	6.0 ± 1.2	6.2 ± 1.0	0.701 0.608	6.0 ± 1.2	6.2 ± 1.0	0.486 0.633
%	6.8 ± 0.8	6.9 ± 0.7		6.8 ± 0.9	6.7 ± 0.7
mmol/L	51 ± 9	52 ± 8		51 ± 10	50 ± 8
PPG (mmol/L)	7.9 ± 3.3	8.2 ± 3.5	0.734	7.9 ± 3.4	7.7 ± 3.2	0.815
TG (mmol/L)	2.4 ± 0.4	2.6 ± 0.5	0.093	2.5 ± 0.4	2.4 ± 0.5	0.396
TC (mmol/L)	5.4 ± 0.7	5.7 ± 0.8	0.128	5.7 ± 0.7	5.3 ± 0.6	0.021
LDL-C (mmol/L)	3.5 ± 0.5	3.8 ± 0.6	0.040	3.7 ± 0.7	3.4 ± 0.6	0.080
CRP (mg/L)	5.1 ± 1.5	7.2 ± 1.7	<0.001	5.5 ± 1.6	5.2 ± 1.3	0.429
SBP (mmHg)	134 ± 7	141 ± 7	<0.001	135 ± 7	132 ± 8	0.127
DBP (mmHg)	86 ± 6	91 ± 6	0.002	87 ± 6	86 ± 5	0.486
LVEDD (mm)	46 ± 6	50 ± 7	0.021	52 ± 8	48 ± 7	0.044
EF (%)	53 ± 5	50 ± 6	0.040	52 ± 5	54 ± 6	0.166
E/A ratio	0.92 ± 0.08	0.77 ± 0.09	<0.001	0.88 ± 0.08	0.93 ± 0.09	0.027

Data are mean ± SD; Abbreviations: BMI body mass index, TG triglyceride, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, PPG postprandial glucose, SBP systolic blood pressure, DBP diastolic blood pressure, CRP C-reactive protein, LVEDD left ventricular end-diastolic diameter, EF ejection fraction

ISSN: 1476-511X